Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioNTech SE ADR rises Tue., outperforms market
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.25% to 5,732.93 and the Dow Jones Industrial Average DJIA rising 0.
BioNTech SE (BNTX) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a
Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,
BioNTech SE ADR rises Monday, outperforms market
The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28% to 5,718.57 and the Dow Jones Industrial Average DJIA rising 0.
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The
5d
on MSN
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
winnipegsun
22h
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
Health Canada approved Pfizer-
BioNTech
’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...
Investor's Business Daily on MSN
7d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Pharmaceutical Technology
20h
BioNTech gets grant for rna lipoplex particles for targeted delivery and storage
Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.
6h
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
13d
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
4d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
11d
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
11h
Who can get an NHS Covid jab this autumn?
The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Pfizer
COVID-19
United States
North Korea
Novavax
Feedback